What is the appropriate prescription for polyethylene glycol 3350 for a 14‑year‑old adolescent with a one‑month history of constipation and intermittent abdominal discomfort?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Prescription for Polyethylene Glycol 3350 in a 14-Year-Old with Constipation

Prescribe polyethylene glycol 3350 (PEG 3350) at 17 grams (approximately one heaping tablespoon) mixed in 4-8 ounces of liquid once daily for this adolescent. 1

Prescription Details

Write the prescription as follows:

Medication: Polyethylene Glycol 3350 powder
Dose: 17 grams (one heaping tablespoon or one capful using provided dosing cup)
Route: Oral
Frequency: Once daily
Instructions: Mix powder in 4-8 ounces of water, juice, soda, coffee, or tea. Stir until dissolved and drink immediately.
Duration: Start with 1-2 weeks, then reassess 1

Rationale for This Dosing

The FDA-approved dose for PEG 3350 is 17 grams daily for occasional constipation 1. While the 2023 AGA-ACG guidelines primarily address adults, they confirm this 17-gram daily dose is effective and has been studied for up to 6 months in chronic constipation 2. This dose significantly increases complete spontaneous bowel movements (CSBMs) by 2.90 per week and spontaneous bowel movements (SBMs) by 2.30 per week compared to placebo 2.

For adolescents, this adult dose of 17 grams daily is appropriate. The pediatric literature supports weight-based dosing of approximately 0.7-0.8 g/kg/day for maintenance therapy 3, 4, which for a typical 14-year-old (50-70 kg) translates to roughly 15-20 grams daily—aligning well with the standard 17-gram dose.

Expected Timeline and Follow-Up

  • First bowel movement: Typically occurs within 2-4 days (48-96 hours) 1
  • Optimal response: Usually achieved between 1-2 weeks 1
  • Duration of therapy: The medication has been shown safe and effective for up to 6 months 2

Reassess after 1-2 weeks. If constipation resolves with several satisfactory bowel movements, the patient may discontinue PEG and transition to lifestyle modifications (adequate dietary fiber, fluid intake, regular exercise) 1.

Important Counseling Points

Common Side Effects

Warn the patient and family about expected mild-to-moderate effects 2:

  • Bloating
  • Flatulence
  • Loose stools or diarrhea
  • Abdominal distension
  • Nausea

These are consistent with osmotic laxative therapy and typically mild 2.

When to Stop or Call

Instruct the patient to discontinue and contact you if 1:

  • Severe diarrhea develops (risk of fluid loss)
  • Unusual cramping or bloating occurs
  • Nausea, vomiting, or abdominal pain develops (may indicate bowel obstruction)
  • Hives or skin rashes appear (allergic reaction)

Contraindications to Verify

Do not prescribe if the patient has 1:

  • Current nausea, vomiting, or abdominal distention (possible bowel obstruction)
  • Known allergy to polyethylene glycol
  • Pregnancy (unless benefits outweigh risks)

Advantages of PEG 3350

PEG 3350 is the preferred first-line osmotic laxative because 2:

  • Strong efficacy: Moderate-quality evidence shows significant improvement in bowel movements and global symptom relief
  • Safety profile: No serious adverse events documented in trials; no clinically significant electrolyte abnormalities 2
  • Accessibility: Available over-the-counter, relatively inexpensive
  • Palatability: Tasteless powder that can be mixed in any beverage 3, 5
  • Long-term use: Safe for extended therapy up to 6 months 2

Clinical Pitfalls to Avoid

  1. Underdosing: The full 17-gram dose is needed for efficacy. Don't start with lower doses in adolescents unless there's a specific reason.

  2. Premature discontinuation: Patients may stop after initial improvement but before establishing regular bowel habits. Emphasize the 1-2 week treatment course.

  3. Inadequate fluid mixing: The powder must be dissolved in adequate liquid (4-8 ounces) for proper osmotic effect 1.

  4. Missing red flags: If the one-month history includes alarm features (weight loss, blood in stool, severe pain), further evaluation is needed before attributing symptoms to functional constipation alone.

  5. Forgetting lifestyle counseling: After successful treatment, discuss dietary fiber intake, hydration, and regular physical activity to prevent recurrence 1.

Alternative Considerations

If PEG 3350 fails or is not tolerated after 1-2 weeks, consider:

  • Increasing dose (can go higher than 17 grams if needed, though this exceeds FDA labeling)
  • Adding or switching to magnesium oxide (though evidence is weaker) 2
  • Fiber supplementation as adjunct therapy 2
  • Referral to pediatric gastroenterology if refractory

The evidence strongly supports PEG 3350 as first-line therapy with excellent safety and efficacy for this clinical scenario 2, 1.

References

Related Questions

What is the appropriate dose of polyethylene glycol 3350 (Miralax) for a 3‑year‑old child weighing 32 lb (≈14.5 kg) with constipation?
What is the recommended dosage and administration of macrogol (polyethylene glycol) for treating functional constipation in children?
What is the appropriate management for a 9‑year‑old child with two weeks of constipation, no bowel movements, who has not responded to polyethylene glycol (PEG 3350, Miralax) despite adequate fiber and fluid intake?
In a child receiving 15 g of Restoralax (polyethylene glycol 3350), do smears and specks on the diaper indicate constipation?
What is the typical acute dose of macrogol (polyethylene glycol 3350) for children with mild encopresis or constipation?
What is the recommended bisacodyl dosage for treating constipation in adults and children?
What is the appropriate diagnostic workup for a 53‑year‑old postmenopausal woman presenting with vaginal bleeding and a palpable left‑lateral mid‑abdominal mass?
What are the recommended ongoing management and surveillance strategies after radiation therapy for a lung mass that shows a mild decrease on follow‑up contrast‑enhanced chest CT?
A 53-year-old man with mild thrombocytopenia (platelet count ~115 ×10⁹/L), mildly elevated alanine aminotransferase (ALT 85 U/L) and aspartate aminotransferase (AST 64 U/L), and a normocytic, normochromic anemia—what is the appropriate work‑up?
In a 53-year-old man with normocytic anemia, mild thrombocytopenia, and mildly elevated transaminases, can these findings cause restless‑legs syndrome?
Should the weekly low‑molecular‑weight heparin (enoxaparin) be held in an 88‑year‑old patient with non‑resolving pneumonia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.